We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+36.21%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.28B
AUM Growth
+$134M
Cap. Flow
-$102M
Cap. Flow %
-7.96%
Top 10 Hldgs %
51.02%
Holding
98
New
23
Increased
17
Reduced
22
Closed
15

Top Buys

1
ALR
Alere Inc
ALR
+$19.9M
2
NBSE
NeuBase Therapeutics, Inc. Common Stock
NBSE
+$14.7M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$12M
4
ARCT icon
Arcturus Therapeutics
ARCT
+$9.78M
5
ACGN
Aceragen Inc
ACGN
+$9.6M

Top Sells

1
VOLC
VOLCANO CORPORATION COM STK
VOLC
+$44.6M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$34.2M
3
AMAG
AMAG Pharmaceuticals
AMAG
+$24.4M
4
ASRT
Assertio
ASRT
+$20.7M
5
KND
Kindred Healthcare
KND
+$20.2M

Sector Composition

1 Healthcare 91.84%
2 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRS
26
DELISTED
Antares Pharma, Inc.
ATRS
$12.7M 0.99%
4,700,000
– –
ELOS
27
DELISTED
Syneron Medical Ltd
ELOS
$12.4M 0.97%
1,005,221
– –
GNCA
28
DELISTED
Genocea Biosciences, Inc.
GNCA
$12.3M 0.96%
+129,375
New +$9.13M
UAM
29
DELISTED
Universal American Corp
UAM
$12.1M 0.94%
1,133,989
-601,564
-35% -$5.65M
ADXS
30
DELISTED
Advaxis Inc
ADXS
$11.6M 0.91%
+53,733
New +$8.26M
CORI
31
DELISTED
Corium International, Inc.
CORI
$11.4M 0.89%
1,736,736
– –
TVTX icon
32
CALL
Travere Therapeutics
TVTX
$5.27B
$11.2M 0.87%
+500,000
New +$7.62M
ATRC icon
33
AtriCure
ATRC
$1.77B
$10.9M 0.85%
533,354
-292,548
-35% -$5.67M
ANTH
34
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$10.8M 0.84%
302,557
+79,580
+36% +$2.36M
VSTM icon
35
Verastem
VSTM
$530M
$10.7M 0.83%
+87,500
New +$9.17M
ANAC
36
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$10.7M 0.83%
184,320
-320,000
-63% -$13.6M
WINT
37
DELISTED
Windtree Therapeutics Inc
WINT
$9.61M 0.75%
576,607
+464
+0.1% +$9.13K
ADMA icon
38
ADMA Biologics
ADMA
$2.02B
$9.45M 0.74%
964,193
+575,000
+148% +$5.79M
TRVN
39
DELISTED
Trevena, Inc.
TRVN
$9.19M 0.72%
2,255
– –
MRTX
40
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$8.98M 0.7%
306,463
+121,707
+66% +$2.86M
ARCT icon
41
Arcturus Therapeutics
ARCT
$172M
$8.76M 0.68%
+222,288
New +$9.78M
CARM
42
DELISTED
Carisma Therapeutics
CARM
$8.62M 0.67%
48,303
-28
-0.1% -$6.12K
GNMX
43
DELISTED
Aevi Genomic Medicine Inc
GNMX
$8.26M 0.64%
1,025,000
– –
TLGT
44
DELISTED
Teligent, Inc
TLGT
$8.16M 0.64%
100,000
+2,519
+3% +$243K
PRTK
45
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$8.14M 0.63%
260,283
– –
FLXN
46
DELISTED
Flexion Therapeutics, Inc.
FLXN
$7.84M 0.61%
348,204
-65,000
-16% -$1.51M
DRRX
47
DELISTED
DURECT Corp
DRRX
$7.46M 0.58%
390,450
-50,000
-11% -$595K
TNXP icon
48
Tonix Pharmaceuticals
TNXP
$198M
– –
0
– –
RDHL
49
Redhill Biopharma
RDHL
$4.29M
$7.05M 0.55%
484
+232
+92% +$3.3M
EPRS
50
DELISTED
EPIRUS BIOPHARMACEUTICALS INC COM
EPRS
$6.94M 0.54%
+775,000
New +$6.23M
1
2
3 4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q1 2015 Portfolio in Review

As of Q1 2015, Broadfin Capital held 98 positions worth $1.28B, up 12% from $1.15B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Broadfin Capital withdrew a net $102M in Q1 2015, closing 15 positions and reducing 22 holdings. Its most notable exit was VOLCANO CORPORATION COM STK, an estimated $44.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 83% a quarter earlier, followed by Consumer Discretionary.

Against the trend, Broadfin Capital opened a new position in Alere Inc worth $22.1M.

  • Broadfin Capital's largest Q1 2015 buy was Alere Inc: 452,423 shares worth $22.1M.
  • Broadfin Capital added most to Aceragen Inc in Q1 2015, an estimated $9.6M increase.
  • Broadfin Capital's biggest Q1 2015 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $34.2M.
  • Broadfin Capital fully exited VOLCANO CORPORATION COM STK in Q1 2015, selling an estimated $44.6M.
  • Broadfin Capital's ten largest holdings make up 51% of its $1.28B portfolio in Q1 2015.
  • Broadfin Capital opened 23 new positions and closed 15 in Q1 2015.
  • Broadfin Capital's portfolio value rose 12% quarter-over-quarter to $1.28B.

Based on Broadfin Capital's 13F filing for Q1 2015, filed 15 May 2015.